Diginex unveils compliance platform as shares dip; C3.ai reports earnings miss and cost cuts

Diginex introduced "Risk-to-Remedy", an end‑to‑end solution for supply‑chain human‑rights due diligence that combines its LUMEN risk‑assessment tool, APPRISE worker‑survey system and the expertise of The Remedy Project. The offering is designed to help companies meet requirements such as the UK Modern Slavery Act, the Australian and Canadian forced‑labour laws, Germany’s Lieferkettengesetz and the EU Forced Labour Regulation. Diginex estimates the market for such compliance services at $3.8 billion in 2025, rising to $9.6 billion by 2034. Despite the product launch, the stock fell, closing at $1.00, down 3.85% on the day and 31% over the past week.

C3.ai reported quarterly and full‑year 2026 financial results that missed market expectations. Quarterly revenue was about $50.2 million, below the consensus range, and the company reaffirmed a full‑year revenue outlook of $246.7‑$250.7 million. Management announced a cost‑reduction program aimed at saving $135 million in annual non‑GAAP operating expenses. The earnings disappointment sent the shares down roughly 8% to €8.90 after market close, underscoring investor concerns about the scalability and profitability of its agentic‑AI platform.